Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2018 | Research

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Authors: Ming-ju Huang, Wei Zhang, Qi Wang, Zhi-jun Yang, Sheng-bin Liao, Li Li

Published in: Journal of Ovarian Research | Issue 1/2018

Abstract

Background

Whether there is a mechanistic link between FOLR1 and response to cisplatin has not been extensively examined. In this study, we determine the expression of FOLR1 in ovarian cancer and examine if FOLR1 levels influence response to cisplatin.

Results

(1) FOLR1 protein expression was lowest in normal ovarian tissue, higher in benign ovarian tumors, and highest in malignant tumors (P < 0.01). (2) FOLR1 expression was decreased in platinum drug-resistant ovarian tumors compared to sensitive tumors (P < 0.01). Consistent with this, FOLR1 expression in tumors progressing following cisplatin treatment was lower than levels in tumors in remission (P < 0.01). (3) FOLR1 was successfully overexpressed at both the mRNA and protein levels following transfection in SKOV3 cells. (4) SKOV3 cells with FOLR1 overexpression were the most sensitive to cisplatin treatment (IC50 = 3.60 μg/ml) and exhibited the highest inhibition rates in the presence of the drug (P < 0.05). (5) The rate of apoptosis of SKOV3 cells increased with cisplatin treatment in a dose- and time-dependent manner (P < 0.05). Cisplatin also induced S phase arrest in a concentration-dependent manner (P < 0.05). Apoptosis and S phase proportion were significantly altered by FOLR1 overexpression (P < 0.05).

Conclusion

FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment.

Leitao MM Jr, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol. 2009;36(2):106–11.CrossRefPubMed

Ragoussis J, Senger G, Trowsdale J, Campbell IG. Genomic organization of the human folate receptor genes on chromosome 11q13. Genomics. 1992;14(2):423–30.CrossRefPubMed

Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 2003;10(12):1018–25.CrossRefPubMed

Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O, Piedrahita JA, Salbaum JM, Kappen C, Weeks BR, James J, et al. Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res. 2005;65(3):887–97.PubMedPubMedCentral

Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol. 1999;26(2 Suppl 6):11–23.PubMed

Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer. 2004;91(2):270–6.CrossRefPubMedPubMedCentral

Dainty LA, Risinger JI, Morrison C, Chandramouli GV, Bidus MA, Zahn C, Rose GS, Fowler J, Berchuck A, Maxwell GL. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol. 2007;105(3):563–70.CrossRefPubMed

Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, Kratz F, Hasenburg A. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008;28(6A):3567–72.PubMed

Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le XF, Cheung AN. Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201.CrossRefPubMedPubMedCentral

10.

Yuan Y, Nymoen DA, Dong HP, Bjorang O, Shih Ie M, Low PS, Trope CG, Davidson B. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol. 2009;40(10):1453–60.CrossRefPubMed

11.

Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol. 2004;95(2):377–83.CrossRefPubMed

12.

Kurosaki A, Hasegawa K, Kato T, Abe K, Hanaoka T, Miyara A, O'Shannessy DJ, Somers EB, Yasuda M, Sekino T, et al. Serum folate receptor alpha as a biomarker for ovarian cancer: implications for diagnosis, prognosis and predicting its local tumor expression. Int J Cancer J Int Cancer. 2016;138(8):1994–2002.CrossRef

13.

Chen YL, Chang MC, Huang CY, Chiang YC, Lin HW, Chen CA, Hsieh CY, Cheng WF. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6(3):360–9.CrossRefPubMed

14.

Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol. 2006;100(1):152–9.CrossRefPubMed

15.

Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gercel-Taylor C. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol. 1997;65(1):13–22.CrossRefPubMed

16.

Jeong JJ, Park N, Kwon YJ, Ye DJ, Moon A, Chun YJ. Role of annexin A5 in cisplatin-induced toxicity in renal cells: molecular mechanism of apoptosis. J Biol Chem. 2014;289(4):2469–81.CrossRefPubMed

17.

Feng X, Li L, Jiang H, Jiang K, Jin Y, Zheng J. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy. Biochem Biophys Res Commun. 2014;444(3):376–81.CrossRefPubMed

18.

Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, et al. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther. 2013;14(11):1032–8.CrossRefPubMedPubMedCentral

19.

Bagnoli M, Canevari S, Figini M, Mezzanzanica D, Raspagliesi F, Tomassetti A, Miotti S. A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol Oncol. 2003;88(1 Pt 2):S140–4.CrossRefPubMed

20.

Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53(19):6811–24.CrossRefPubMed

Title: FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells
Authors: Ming-ju Huang
Wei Zhang
Qi Wang
Zhi-jun Yang
Sheng-bin Liao
Li Li
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-018-0387-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Abstract

Background

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Does a poor-quality embryo have an adverse impact on a good-quality embryo when transferred together?

Preoperative assessment of ovarian tumors using a modified multivariate index assay

Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types

Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing

Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death